Create an Account
  1. Home
  2. Specialty
  3. Retina

AMD 2017: A Review of Treatment Guidelines and the Role of Early Appropriate Therapy - Part 2

AMD 2017 A Review of Treatment Guidelines and the Role of Early Appropriate Therapy Part 2
Media formats available:
Details
Presenters

  • Overview

    As newer therapies enter the market, treatment options and dosing strategies can be impacted by the cost of treatment, which continues to be a major factor in treatment planning. Clinicians need to consider multiple treatment options in order to properly gauge the right treatment plan for any given patient’s needs. Ophthalmologists are also only one part of the treatment paradigm for patients with diabetes; as previously described these patients tend to have other manifestations of the systemic disorder and treatment is multifactorial. Grantor Statement This continuing medical education activity is supported through an educational grant from Regeneron Pharmaceuticals, Inc.

  • Learning Objectives

    Upon completion of this activity, the participant should be able to:

    • Assess the most recent monotherapy and combination therapy clinical study evidence using available anti-VEGF therapies for common retinal diseases, including DME
    • Discuss the ocular and systemic effects of anti-VEGF therapies and how to educate patients on appropriate expectations
    • Develop plans to initiate treatment for conditions, such as DME, using anti-VEGF agents, as well as better understand when to change therapeutic strategies

  • Accreditation

    Accreditation Statement

    Evolve Medical Education LLC is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education to physicians.

     

    Credit Designation Statement

    Evolve Medical Education LLC designates this enduring material for a maximum of 1 AMA PRA Category 1 Credit ™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

     

  • Faculty and Disclosures

    DISCLOSURE POLICY
    It is the policy of Evolve that faculty and other individuals who are in the position to control the content of this activity disclose any real or apparent conflicts of interest relating to the topics of this educational activity. Evolve has full policies in place that will identify and mitigate all conflicts of interest prior to this educational activity.

    Disclosure Policy Statement

    It is the policy of Evolve Medical Education LLC that faculty and other individuals who are in the position to control the content of this activity disclose any real or apparent conflict of interests relating to the topics of this educational activity. Evolve Medical Education LLC has full policies in place that will identify and resolve all conflicts of interest prior to this educational activity.

    The following faculty members have the following financial relationships with commercial interests:

    David Eichenbaum, MD has had a financial agreement or affiliation during the past year with the following commercial interests in the form of Consultant/Advisory Board/Speaker’s Bureau:  Alcon; Alimera Sciences; Allergan; Genentech, Inc; Ophthotech Corporation; and Regeneron Pharmaceuticals, Inc. Grant/Research Support: Alcon; Alimera Sciences; Allergan; Genentech, Inc; Ophthotech Corporation;  and River Vision. Stock/Shareholder: Hemera Biosciences and US Retina.

    Chirag P. Shah, MD, MPH has had a financial agreement or affiliation during the past year with the following commercial interests in the form of Grant/Research Support: Genentech, Inc. and Regeneron Pharmaceuticals, Inc.

    Cheryl Cavanaugh, MS, Evolve Medical Education LLC; and Michelle Dalton, Writer, have no relevant commercial interests to disclose.

    Rishi P. Singh, MD, Peer Reviewer, has had a financial agreement or affiliation during the past year with the following commercial interests in the form of Consultant/Advisory Board/Speaker’s Bureau:  Alcon; Genentech, Inc; Regeneron Pharmaceuticals, Inc; and ThromboGenics NV. Grant/Research Support: Alcon; Genentech, Inc; Regeneron Pharmaceuticals, Inc.

  • Disclaimer

    Off-Label Statement

    This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by FDA. The opinions expressed in the educational activity are those of the faculty. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications and warnings.

     

    Disclaimer

    The views and opinions expressed in this educational activity are those of the faculty and do not necessarily represent the views of Evolve Medical Education LLC or Regeneron Pharmaceuticals Inc.

  • System Requirements

    • Supported Browsers (2 most recent versions):
      • Google Chrome for Windows, Mac OS, iOS, and Android
      • Apple Safari for Mac OS and iOS
      • Mozilla Firefox for Windows, Mac OS, iOS, and Android
      • Microsoft Edge for Windows
    • Recommended Internet Speed: 5Mbps+

  • Publication Dates

    Release Date:

    Expiration Date:

Ready to Claim Your Credits?

You have attempts to pass this post-test. Take your time and review carefully before submitting.

Good luck!

LIVE ON REACHMD RADIOBack to live radio
ReachMD Radio

Loading...

00:00
00:00
    Register

    We're glad to see you're enjoying Evolve Medical Education…
    but how about a more personalized experience?

    Register for free